Impact of non-motor fluctuations on QOL in patients with Parkinson’s disease
Objective: To investigate the impact of non-motor fluctuations for QOL in patients with Parkinson's disease (PwPD) using a nine-item wearing-off questionnaire (WOQ-9). Background: Long-term levodopa…Efficacy of levodopa/carbidopa/entacapone replacement of levodopa/dopa decarboxylase inhibitors in treatment of Chinese Parkinson’s disease patients with wearing-off: a multicenter, randomized controlled, open label study
Objective: This study aimed to investigate the efficacy and safety comparison between LCE and Pramexol in Chinese PD patients with the wearing-off phenomenon. Background: Wearing…Measuring the heterogeneity of disease progression in Parkinson’s disease with multimodal clinical milestones over 10 years in the DeNoPa cohort
Objective: To provide a reference of individual Parkinson’s disease (PD) progression by assessing multimodal milestones over 10 years (y) in patients of the DeNoPa cohort.…COPS: Continuous Observation of Parkinsonian Symptoms – A prospective data acquisition study using wearable accelerometery
Objective: To investigate the continuous and objective assessment of motor symptom severity in Parkinson’s Disease (PD) in everyday life. Background: Treatment adjustments in PD patients…Motor function in Parkinson´s disease during 16h treatment with intravenously (DIZ101), subcutaneously (DIZ102), or intestinally (LCIG) infused levodopa
Objective: To compare the effect of intravenous (DIZ101) and subcutaneous (DIZ102) continuous 16h infusion of a continuously buffered acidic levodopa/carbidopa solution with levodopa/carbidopa intestinal gel…How do people with Parkinson’s disease experience self-optimization of treatment using digitally supported symptom monitoring?
Objective: The aim of this study was to investigate how people with Parkinson´s disease experience an intervention of optimizing their own medical treatment through digitally…Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease
Objective: To evaluate the profile of those patients with advanced Parkinson’s Disease (APD) in which we decided to use continuous 24-hour administration of Levodopa Carbidopa…The impact of wearing ‘OFF’ (WO) episodes on non-motor symptoms (NMS) burden and quality of life (QoL) in Parkinson’s disease (PD) patients
Objective: To estimate the frequency and severity of NMS and their impact on QoL among patients with moderate to advanced PD with WO episodes versus…Fecal tyrosine decarboxylase and motor response complications in Parkinson’s Disease
Objective: To investigate the clinical correlates of gut microbe-derived tyrosine decarboxylase (tdc) and motor dysfunction in Parkinson’s Disease (PD) patients. Background: Gut microbe-derived tdc was…Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)
Objective: An analysis of the proportion of patients who turned ON after levodopa inhalation powder (CVT-301) 84mg treatment vs placebo, compared across subgroups of patients…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 24
- Next Page »